Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., For more information, please visit www.virpaxpharma.com. About Altasciences. Christopher M.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., For more information visit www.marinuspharma.com.

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. Logo – [link]. SOURCE SciSparc Ltd.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

Most official studies conducted on CBD for anxiety conclude with tentative support for CBD as an appropriate treatment for anxiety, but researchers in virtually every case suggest that more information is needed on an individual level to determine the appropriateness of using cannabis to treat anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Veriheal

APRIL 11, 2022

Additionally, numerous other cannabis-based medications have already gained approval or are in the process of being tested in clinical trials. federal law, from which point, informed choices can be made about the use of cannabis and cannabinoids. The post New U.S.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Miss Marijuana

FEBRUARY 7, 2025

It’s important to stay informed about current laws because they affect everything from what products are available to how they can be used. Keep up to date with reliable sources, like NORML , to stay informed about the latest developments. When we talk about federal vs. state regulations , it gets interesting.

THC 52

THC CBD Chronic Pain Cannabinoids 52

Cannabis Law Report

SEPTEMBER 20, 2021

Nanomerics”) to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children. For more information, please visit www.virpaxpharma.com. Forward-Looking Statement. Christopher M. Chipman, CPA. Chief Financial Officer. Betsy Brod.

Epilepsy 40

Epilepsy Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

DECEMBER 23, 2021

The story of GW Pharmaceuticals, the producers of Epidiolex, is instructive regarding the challenges and opportunities of operating in the pharmaceutical cannabis space; taking over 20 years to generate considerable sales and facing several setbacks in clinical trials. For more information about this report visit [link].

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

SpeedWeed

MARCH 30, 2021

Dr Daniel Couch, Medical Lead at the UK Centre For Medicinal Cannabis welcomed the move as a sensible way of establishing an evidence base that will inform prescribing and future Randomised Controlled Trials (RCT). Private Clinic Happy To Help. “For For background on its launch see here ). Boost For NHS Cannabis Prescribing .

Data 52

Data Patients Clinical Trials Business 52

CannaTech

SEPTEMBER 16, 2018

Many healthcare practitioners possess a knowledge gap about cannabis, as their medical school curriculum didn’t include any information on the topic. Over time extended clinical trials will continue to map out the plant’s therapeutic effects, supporting it as an alternative medicine offering relief for a long list of conditions.

Education 66

Education Medicine Clinical Trials Patients 66

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. The perception that CBD is a wonder-drug version of cannabis — particularly known for its uses to treat epilepsy — that doesn’t get you high.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

SEPTEMBER 6, 2021

Clinical trials, research and development (R&D) activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market. 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications. Key Topics Covered: 1 Preface. 4 Introduction.

Chronic Pain 66

Chronic Pain Research and Development Clinical Trials Epilepsy 66

Cannabis Law Report

NOVEMBER 24, 2019

Finding more information and committee details. Severe treatment-resistant epilepsy. People have the right to be involved in discussions and make informed decisions about their care, as described in your care. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. Recommendations.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Epilepsy & behavior case reports 9 (2018): 10. How Do CBD Drug Interactions Occur? Alsherbiny, Muhammad, and Chun Li. Medicinal Cannabis—Potential Drug Interactions.”

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

SEPTEMBER 9, 2021

Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. Global Legal Cannabis Industry: Number of Clinical Trials, By Region. Market Segmentation. Market Dynamics.

Recreational 73

Recreational Hemp THC Legalization 73

Cannabis Law Report

JANUARY 10, 2022

This high share is attributable to the rising adoption of THCV for various applications such as epilepsy, arthritis, metabolic disorders, neurological disorders, and pain management. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 40

Cannabinoids Clinical Trials Research and Development Supply Chain 40

Peninsula Alternative Health

MAY 15, 2019

With clinical research developing rapidly in Israel and with the use of innovative technology we hope to have this information in the near future. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Topical 40

Cannabis Law Report

JANUARY 13, 2020

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Nabiximols (known as “Sativex” outside US) in the US: Commence pivotal clinical program in initial target indication of spasticity associated with Multiple Sclerosis.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

CannaMD

AUGUST 8, 2020

For more information, see: What Is Hemp & Why Does It Matter? ). Designed to treat seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome , Epidiolex is a purified (> 98% oil-based) CBD extract administered via oral spray. Why is hemp CBD illegal in some states?

CBD 105

CBD DEA Research and Development Hemp 105

Cannabis Law Report

OCTOBER 5, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. Cautionary Statement Regarding Forward-Looking Statements. Investor: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com. Media: media@mymd.com.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Media 40

Cannabis Law Report

OCTOBER 19, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. 646) 421-9523.

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

DECEMBER 28, 2021

The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., But despite the growing popularity of CBD items, various myths surround this product that make it difficult for some individuals to make an informed decision.

CBD 52

CBD Clinical Trials Consumption Chronic Pain 52

Cannabis Law Report

DECEMBER 29, 2021

The company has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial and preparations to begin that trial are underway. Oravax is also preparing to commence clinical trials in Israel. For more information, visit www.mymd.com.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain CBD 40

Cannabis Law Report

NOVEMBER 18, 2021

“Oravax has received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in-human clinical trial for its oral COVID-19 vaccine, and preparations to begin the trial are underway. Oravax is also preparing to commence clinical trials in Israel.”. 646) 421-9523.

Pharmaceutical 40

Pharmaceutical Clinical Trials Business Chronic Pain 40

Cannabis Law Report

DECEMBER 1, 2021

The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. Robert Schatz.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

Cannabis Law Report

AUGUST 19, 2019

The Therapeutic Goods Administration (TGA), Australia’s medicines regulatory body (akin to the FDA in the USA and EMA in Europe), is currently collecting some potentially useful information from doctors prescribing medicinal cannabis around the progress of their patients.

Medicine 45

Medicine Patients Clinical Trials Access 45

Cannabis Law Report

SEPTEMBER 22, 2021

Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

MMJ Recs

JULY 5, 2024

Neurological Disorders Research suggests THC may benefit neurological conditions such as epilepsy, multiple sclerosis (MS), and Parkinson’s disease. Numerous clinical trials are underway to further investigate THC’s efficacy, safety, and potential interactions with other medications as well.

THC 52

THC Research and Development Chronic Pain Cannabinoids 52

Cannabis Law Report

MARCH 21, 2019

With so much random information being thrown around the internet, it can be very difficult to differentiate what is true and what is false. THC for patients who suffer from severe epilepsy and is produced in compliance with the North Carolina Industrial Hemp Commission regulations. AUTHOR: Felipe Rivera. contact@emperorcbd.com.

State Laws 55

State Laws Law CBD Legalization 55

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals. Christopher M.

Research and Development 40

Research and Development Clinical Trials Pharmaceutical Chronic Pain 40

Cannabis Law Report

OCTOBER 26, 2021

MyMD plans to advance MYMD-1 in the clinic with two simultaneous Phase 2 trials beginning in the current quarter, one for delaying aging and prolonging healthy lifespan, and the second for COVID-19-associated depression and cytokine elevation. For more information, visit www.mymd.com. Dr. Chapman Bio. MyMD: Robert Schatz.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax has acquired the exclusive worldwide rights from Nanomerics to use its MET platform for the nasal delivery of CBD for the management of epilepsy in children (a rare pediatric disease) and adults.

Pharmaceutical 40

Pharmaceutical Research and Development Clinical Trials Chronic Pain 40

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. 646) 421-9523.

Pharmaceutical 40

Pharmaceutical Clinical Trials Research and Development Therapy 40

The Joint Blog

FEBRUARY 24, 2021

Numerous trials have been run using medical marijuana and CBD tinctures to treat or reduce the symptoms of Parkinson’s Disease. This is not the first medicinal trial of its kind. Cannabis and CBD oils have often been used to reduce the effects of epilepsy and several other neurological issues, so why not Parkinson’s?

Treatment 55

Treatment Clinical Trials Collective Patients 55

Cannabis Law Report

NOVEMBER 23, 2021

The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy. For more information, visit www.mymd.com. Cautionary Statement Regarding Forward-Looking Statements. MyMD Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com.

Pharmaceutical 40

Pharmaceutical Clinical Trials Therapy Chronic Pain 40